Diabetes, obesity & metabolism · 2026
Genetically Proxied GIP-GIPR Pathway Perturbation and Fracture Risk.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cheng Wenjie, Liu Weijie, Wei Jie, Zeng Chao, Lyu Houchen, Zhao Sizheng Steven
Аннотация
AIMS: To determine whether genetic proxies for incretin pathway perturbation are associated with fracture risk and bone mineral density, providing human genetic evidence relevant to the skeletal safety of incretin-based therapies.
MATERIALS AND METHODS: We conducted drug-target Mendelian randomisation using cis genetic variants near GIP, GIPR, GCG, GLP1R in 401 983 unrelated UK Biobank participants. Instruments were scaled to 1 kg/m2 lower BMI or 1 mmol/mol lower HbA1c. Outcomes included fractures at major osteoporotic sites, combined spine-and-hip fractures, site-specific fractures and estimated bone mineral density (eBMD). We compared these estimates with genome-wide liability to lower BMI or HbA1c to contextualise the fracture associations observed for the target-proximal instruments. We used Cox models to estimate time-to-fracture associations per SD of target genetic risk score aligned to lower BMI or HbA1c.
RESULTS: GIP-GIPR perturbation was associated with lower odds of fractures at major osteoporotic sites when scaled to lower BMI (OR 0.80, 95% CI 0.66-0.98) or lower HbA1c. Associations were similar for combined spine-and-hip fractures under both scaling approaches (OR 0.68, 0.49-0.94). Genome-wide liability to lower BMI or HbA1c did not show the same fracture associations as GIP-GIPR perturbation. GCG-GLP1R estimates were imprecise. Genetically proxied incretin pathway perturbation was not associated with eBMD. In Cox analyses, GIP-GIPR genetic risk score was associated with lower risk of fractures at major osteoporotic sites (HR 0.976, 0.959-0.992) and combined spine-and-hip fractures (HR 0.971, 0.946-0.996).
CONCLUSIONS: Human genetic evidence suggests an association between genetically proxied GIP-GIPR pathway perturbation and lower fracture risk, supporting fracture-focused evaluation of GIPR-targeting therapies in clinical and post-marketing studies.
MATERIALS AND METHODS: We conducted drug-target Mendelian randomisation using cis genetic variants near GIP, GIPR, GCG, GLP1R in 401 983 unrelated UK Biobank participants. Instruments were scaled to 1 kg/m2 lower BMI or 1 mmol/mol lower HbA1c. Outcomes included fractures at major osteoporotic sites, combined spine-and-hip fractures, site-specific fractures and estimated bone mineral density (eBMD). We compared these estimates with genome-wide liability to lower BMI or HbA1c to contextualise the fracture associations observed for the target-proximal instruments. We used Cox models to estimate time-to-fracture associations per SD of target genetic risk score aligned to lower BMI or HbA1c.
RESULTS: GIP-GIPR perturbation was associated with lower odds of fractures at major osteoporotic sites when scaled to lower BMI (OR 0.80, 95% CI 0.66-0.98) or lower HbA1c. Associations were similar for combined spine-and-hip fractures under both scaling approaches (OR 0.68, 0.49-0.94). Genome-wide liability to lower BMI or HbA1c did not show the same fracture associations as GIP-GIPR perturbation. GCG-GLP1R estimates were imprecise. Genetically proxied incretin pathway perturbation was not associated with eBMD. In Cox analyses, GIP-GIPR genetic risk score was associated with lower risk of fractures at major osteoporotic sites (HR 0.976, 0.959-0.992) and combined spine-and-hip fractures (HR 0.971, 0.946-0.996).
CONCLUSIONS: Human genetic evidence suggests an association between genetically proxied GIP-GIPR pathway perturbation and lower fracture risk, supporting fracture-focused evaluation of GIPR-targeting therapies in clinical and post-marketing studies.